Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PAVmed Inc. (PAVM:NASDAQ), powered by AI.
PAVmed Inc. is currently trading at $4.99. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for PAVmed Inc. on Alpha Lenz.
PAVmed Inc.'s P/E ratio is 8.3.
“PAVmed Inc. trades at a P/E of 8.3 (undervalued) with modest ROE of 2.5%.”
Ask for details →PAVmed Inc. is a medical device company focused on developing innovative technologies to address unmet medical needs. The company aims to enhance patient care through minimally invasive medical solutions across various domains. PAVmed operates in sectors such as diagnostics, medical devices, and healthcare technologies. It manages a diverse portfolio of products and subsidiaries, including Lucid Diagnostics, which specializes in diagnostic tools for esophageal health, and Solys, aimed at delivering advanced biomaterial solutions. The company leverages a unique approach by quickly advancing products from concept to commercialization, striving to bring practical and efficient innovations to the healthcare industry. Headquartered in New York, PAVmed is positioned to impact the medical device market significantly by targeting high-growth healthcare segments and addressing crucial patient needs through technology advancements.
“PAVmed Inc. trades at a P/E of 8.3 (undervalued) with modest ROE of 2.5%.”
Ask for details →PAVmed Inc. (ticker: PAVM) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 39 employees. Market cap is $3M.
The current price is $4.985 with a P/E ratio of 8.33x and P/B of 0.1x.
ROE is 2.55% and operating margin is -30126.76%. Annual revenue is $71,000.